Company intelligence / Profile preview

Brixun Pharmaceutical

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Brixun Pharmaceutical is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule targeted therapies for oncology. The company specializes in developing next-generation inhibitors to overcome resistance mechanisms in lung cancer, particularly targeting EGFR and ALK mutations. Brixun aims to provide more effective and safer treatment options for patients with advanced solid tumors through its internal R&D capabilities. Headquartered in China, the company is advancing several candidates through early to mid-stage clinical trials.

Therapeutic areas: Oncology
Modalities: Small moleculeTargeted therapy
Industry: Biotech

Beyond the preview

Go deeper on Brixun Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brixun Pharmaceutical.

Explore the full profile